Horenshtein Hadar Mirit 4

What Happened Mirit Horenshtein Hadar, Chief Financial Officer and Secretary of Silexion Therapeutics Corp (SLXN), was granted 49,726 restricted share units (RSUs) that were fully vested and immediately settled into 49,726 ordinary shares on February 20, 2026. The Form 4 reports the acquisition price as $0.00 (award/settlement), so this was a compensation award rather than an open-market purchase.

Key Details

• Transaction date: February 20, 2026; Form 4 filed February 23, 2026 (filed in a timely manner).
• Transaction type/code: Award/Grant (A) — fully vested RSUs immediately settled for underlying shares.
• Shares acquired: 49,726 ordinary shares; reported acquisition price $0.00.
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes: (F2) RSUs were fully vested and immediately settled for underlying shares; grant approved by the board. (F1) Reported share counts reflect adjustments for the issuer's 1-for-9 and 1-for-15 reverse splits in Nov 2024 and Jul 2025.
• No 10b5-1 plan, tax-withholding sale, or late-filing flag noted in the filing.

Context This was a compensatory award (RSUs) settled into stock, not a market purchase or sale — common for executive compensation and not necessarily a signal of personal buying/selling intent. Because the RSUs were immediately settled, there was no option exercise or cashless sale involved; the filing simply records the issuance/settlement of shares to the officer.